Stocks
Stocks
Last updated: June 5, 2026
This comparison evaluates Charles River Laboratories and Robert Half Inc. as long-term investment options, focusing on financial stability, growth potential, and risk factors. While Charles River offers a robust revenue base within the healthcare sector, Robert Half presents a more stable profit margin and dividend yield, making each suitable for different investor profiles.
| Aspect | Charles River Laboratories Inte | Robert Half Inc. | Winner |
|---|---|---|---|
| Market Capitalization | Approximately $8.95 billion | $3.23 billion | Charles River Laboratories Inte |
| Profit Margin | -4.585% | 2.43% | Robert Half Inc. |
| Dividend Yield | None | 7.98% | Robert Half Inc. |
| Beta (Volatility Measure) | 1.446 | 0.792 | Robert Half Inc. |
| Price-to-Earnings (PE) Ratio | PE ratio not available (negative EPS) | 24.31 | Robert Half Inc. |
Market Capitalization: Charles River Laboratories' larger market cap indicates a more established presence and greater long-term stability within healthcare stocks, potentially providing more resilience during market downturns.
Profit Margin: Robert Half’s positive profit margin suggests consistent profitability, an essential factor for long-term investors seeking stable returns, whereas Charles River is currently operating at a loss.
Dividend Yield: Robert Half offers a high dividend yield of nearly 8%, making it attractive for income-focused long-term investors, unlike Charles River, which does not currently pay dividends.
Beta (Volatility Measure): Robert Half’s lower beta indicates less stock price volatility, making it a potentially safer long-term investment during economic fluctuations compared to the more volatile Charles River.
Price-to-Earnings (PE) Ratio: Robert Half’s PE ratio of 24.31 reflects expected growth and profitability, whereas Charles River’s negative EPS indicates current losses, which could be a risk factor for long-term growth.
Charles River Laboratories operates within the Diagnostics & Research industry of the Healthcare sector, with a market capitalization of approximately $8.95 billion and revenue nearing $4.03 billion. Despite its impressive revenue, the company is currently experiencing a loss with an EPS of -3.71 and a negative profit margin of -4.58%. Its beta of 1.446 suggests it is more volatile than the broader market, posing a higher risk for long-term investors seeking stability. The stock price has ranged from a 52-week low of $140.78 to a high of $228.88, reflecting significant price swings over the past year. Its forward PE of around 15 indicates moderate valuation, but the lack of dividends and ongoing losses could hinder long-term income growth.
In contrast, Robert Half Inc. is a leader in Staffing & Employment Services within the Industrials sector, with a market cap of approximately $3.23 billion and revenue of about $5.33 billion. The company reports a positive EPS of 1.3, with a profitable margin of 2.43%, demonstrating consistent profitability. Its beta of 0.792 indicates lower volatility, making it more stable in uncertain economic conditions. Notably, Robert Half offers a substantial dividend yield of 7.98%, perfect for investors prioritizing income continuity over time. The stock has traded between $21.83 and $45.67 in the past year, reflecting more stable price behavior. Its PE ratio of approximately 24.31 suggests that the stock is valued for growth, and its steady earnings make it a reliable long-term holding.
Overall, Charles River’s sizable market cap and revenue base are promising for long-term growth within healthcare, but its current losses and lack of dividends introduce risk. Conversely, Robert Half’s profitability, dividend yield, and lower volatility make it a safer long-term investment, especially for income-focused portfolios. The decision hinges on investor preference for growth potential versus income stability, with Robert Half being the more conservative choice for long-term stability and Charles River offering growth prospects in the healthcare sector that might require patience during recovery phases.
Robert Half Inc. emerges as the more balanced long-term investment due to its consistent profitability, attractive dividend yield, and lower stock volatility. However, Charles River Laboratories holds long-term growth potential within the healthcare sector, provided it can turn around its current losses. For risk-averse investors prioritizing income, Robert Half is the better choice; for those seeking growth and willing to accept higher volatility, Charles River offers substantial upside.
Investors seeking exposure to the healthcare diagnostics and research industry with a focus on growth potential, despite current losses. Suitable for long-term investors willing to endure volatility for potential future gains.
Investors prioritizing stable income with high dividend yields, lower volatility, and consistent profitability. Ideal for conservative, income-focused long-term portfolios.